Sylvia Hsu, MD

Publications

Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison, WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A Weinstein GD, Young M, Horn L.  From the Medical Board of the Nation Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis.  J Am Acad Dermatol 2008; 58(1): 94-105.

Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59(2): 209-217.

Doherty SD, Hsu S. A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008; 7(8): 769-773.

Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, Kalb RE, Hsu S. Treatment of Severe Scalp Psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009; 60(6): 962-71.

Rosenbach M, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Van Voorhees AS. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62(4): 655-62.

Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE.  Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62(2): 291-299.

Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin 2010; 28(3): 577–586.

Chen M, Holland MJ, Mir MR, Wong MG, Kelley BP, Bhuchar SS, Grim KD, Hsu S. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors. J Drugs Dermatol 2011; 10(3): 280-284.

Bremmer S, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF Jr, Blauvelt A. Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 63: 1058-69.

Frankel A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl M, Bebo BF, Gottlieb A. In response to “Treatment of psoriasis with cyclosporine in patients with hepatitis C infection: Risk or opportunity?” J Am Acad Dermatol 2011; 64(4): 788-791.

Pugliese DJ, Gottlieb AB, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo BF, Blauvelt A, Van Voorhees AS. Treatment of psoriasis in the setting of excessive alcohol intake: From the Medical Board of the National Psoriasis Foundation. Psoriasis Forum 2011.

Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF, Korman NJ. Psoriasis in the elderly: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2011; 65:537-45.

Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012.

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148(1): 95-102.

Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF, Kalb RE. Treatment of pustular psoriasis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67(2): 279-88.

Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2014; 70(1): 168-177.

Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.  J Am Acad Dermatol 2014; 70(1): 178-186.

Doherty SD, Van Voorhees AS, Lebwohl MG, Korman NJ, Hsu S. Reply to: Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treatment with tumor necrosis factor-alfa inhibitors.” J Am Acad Dermatol 2015; 72(4):744.

Doherty SD, Lebwohl MG, Van Voorhees AS, Korman NJ, Hsu S.  Annual screening for tuberculosis in patients on TNF-alfa antagonists. J Am Acad Dermatol 2015;73(3):e123.

Huang YYM, Hsu S. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: update and commentary. J Am Acad Dermatol. 2017;76(6):e221.

Malviya N, Albrecht J, Amerson E, Colven R, Hsu S, Maurer T, McLellan B, Pomeranz M, Chong BF. Assessment of dermatology clinic resources at safety-net hospitals: results from a national survey. J Am Acad Dermatolol 2017;77(5): 977-978.

Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372-374.